Haeun Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haeun Lee has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Martin
Biomedical Informatics and Data Science The Johns Hopkins University School of Medicine Baltimore Maryland USA
2 shared publications - Ho-Young Lee
Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
2 shared publications - Hui-Woun Moon
Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
2 shared publications - Kwangsoo Kim
Department of Transdisciplinary Medicine Seoul National University Hospital Seoul Republic of Korea
2 shared publications Paul Nagy
Biomedical Informatics and Data Science, Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2 shared publications- Se Young Jung
Department of Family Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by Elsevier in Ophthalmology
- Vol. 133 (10) , 1221-1229
Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study
- 2 June 2026
- Published by Elsevier in Ophthalmology
- Vol. 133 (10) , 1221-1229
Open AccessSemaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study
- 1 May 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (5) , e323399
Comparison of Cardiovascular Events in Patients Receiving Concomitant Clopidogrel and Proton Pump Inhibitors Classified by CYP2C19 Inhibitory Potency
BACKGROUND: Proton pump inhibitors (PPIs) may potentially reduce clopidogrel’s antiplatelet effect and increase cardiovascular risk. The degree of CYP (cytochrome P450) 2C19 inhibition varies among PPIs. Few studies have evaluated individual PPIs by CYP2C19 inhibition strength across countries. This study aimed to compare the incidence of cardiovascular events between strong CYP2C19-inhibiting potency and weak CYP2C19-inhibiting potency (weak or non-CYP2C19–inhibiting PPIs) in patients receiving clopidogrel. METHODS: We conducted an international observational cohort study using 14 databases from the United States, South Korea, and Taiwan. We included patients aged ≥18 years who received clopidogrel with PPIs from 1985 to 2023. PPIs were classified into strong CYP2C19-inhibiting PPIs and weak or non-CYP2C19–inhibiting PPIs based on CYP2C19 inhibition. We compared the hazard ratios and 95% CIs for major adverse cardiovascular events, including myocardial infarction, stroke, and cardiovascular mortality, using the Cox proportional hazards model after 1:1 propensity score matching. Secondary outcomes included cardiovascular mortality, myocardial infarction, stroke, and all-cause mortality. A random-effects model calculated pooled hazard ratios and 95% CIs. Only databases meeting all diagnostic criteria were included in the meta-analysis. RESULTS: Large-scale propensity score matching identified 166 005 patient pairs. During the 365-day follow-up, the risk of major adverse cardiovascular events did not differ significantly between patients receiving clopidogrel plus strong CYP2C19-inhibiting PPIs and those receiving clopidogrel plus weak or non-CYP2C19–inhibiting PPIs (17.63 per 1000 person-years versus 16.82 per 1000 person-years; calibrated hazard ratio, 1.00 [95% CI, 0.79–1.26]). No significant difference was observed in the risk of secondary outcomes (calibrated hazard ratio, cardiovascular mortality 1.10 [95% CI, 0.87–1.39], myocardial infarction 0.98 [95% CI, 0.81–1.19], stroke 1.05 [95% CI, 0.87–1.27], and all-cause mortality 1.18 [95% CI, 0.93–1.50]). CONCLUSIONS: Concomitant use of clopidogrel and strong CYP2C19-inhibiting PPIs was not associated with a higher cardiovascular risk compared with concomitant use of clopidogrel and weak or non-CYP2C19–inhibiting PPIs. This large-scale study does not support the clinical significance of potential interactions between PPIs and clopidogrel.
- 1 May 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (5) , e323399
Comparison of Cardiovascular Events in Patients Receiving Concomitant Clopidogrel and Proton Pump Inhibitors Classified by CYP2C19 Inhibitory Potency
BACKGROUND: Proton pump inhibitors (PPIs) may potentially reduce clopidogrel’s antiplatelet effect and increase cardiovascular risk. The degree of CYP (cytochrome P450) 2C19 inhibition varies among PPIs. Few studies have evaluated individual PPIs by CYP2C19 inhibition strength across countries. This study aimed to compare the incidence of cardiovascular events between strong CYP2C19-inhibiting potency and weak CYP2C19-inhibiting potency (weak or non-CYP2C19–inhibiting PPIs) in patients receiving clopidogrel. METHODS: We conducted an international observational cohort study using 14 databases from the United States, South Korea, and Taiwan. We included patients aged ≥18 years who received clopidogrel with PPIs from 1985 to 2023. PPIs were classified into strong CYP2C19-inhibiting PPIs and weak or non-CYP2C19–inhibiting PPIs based on CYP2C19 inhibition. We compared the hazard ratios and 95% CIs for major adverse cardiovascular events, including myocardial infarction, stroke, and cardiovascular mortality, using the Cox proportional hazards model after 1:1 propensity score matching. Secondary outcomes included cardiovascular mortality, myocardial infarction, stroke, and all-cause mortality. A random-effects model calculated pooled hazard ratios and 95% CIs. Only databases meeting all diagnostic criteria were included in the meta-analysis. RESULTS: Large-scale propensity score matching identified 166 005 patient pairs. During the 365-day follow-up, the risk of major adverse cardiovascular events did not differ significantly between patients receiving clopidogrel plus strong CYP2C19-inhibiting PPIs and those receiving clopidogrel plus weak or non-CYP2C19–inhibiting PPIs (17.63 per 1000 person-years versus 16.82 per 1000 person-years; calibrated hazard ratio, 1.00 [95% CI, 0.79–1.26]). No significant difference was observed in the risk of secondary outcomes (calibrated hazard ratio, cardiovascular mortality 1.10 [95% CI, 0.87–1.39], myocardial infarction 0.98 [95% CI, 0.81–1.19], stroke 1.05 [95% CI, 0.87–1.27], and all-cause mortality 1.18 [95% CI, 0.93–1.50]). CONCLUSIONS: Concomitant use of clopidogrel and strong CYP2C19-inhibiting PPIs was not associated with a higher cardiovascular risk compared with concomitant use of clopidogrel and weak or non-CYP2C19–inhibiting PPIs. This large-scale study does not support the clinical significance of potential interactions between PPIs and clopidogrel.
- 20 January 2026
- Published by Elsevier in Journal of Biomedical Informatics
- Vol. 174, 104989
A multidimensional hierarchical framework for sources of bias in real-world healthcare evidence: a scoping review
- 20 January 2026
- Published by Elsevier in Journal of Biomedical Informatics
- Vol. 174, 104989
A multidimensional hierarchical framework for sources of bias in real-world healthcare evidence: a scoping review
- Open Access
- 22 November 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e59260
Hospital Length of Stay Prediction for Planned Admissions Using Observational Medical Outcomes Partnership Common Data Model: Retrospective Study
Background: Accurate hospital length of stay (LoS) prediction enables efficient resource management. Conventional LoS prediction models with limited covariates and nonstandardized data have limited reproducibility when applied to the general population. Objective: In this study, we developed and validated a machine learning (ML)–based LoS prediction model for planned admissions using the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM). Methods: Retrospective patient-level prediction models used electronic health record (EHR) data converted to the OMOP CDM (version 5.3) from Seoul National University Bundang Hospital (SNUBH) in South Korea. The study included 137,437 hospital admission episodes between January 2016 and December 2020. Covariates from the patient, condition occurrence, medication, observation, measurement, procedure, and visit occurrence tables were included in the analysis. To perform feature selection, we applied Lasso regularization in the logistic regression. The primary outcome was an LoS of 7 days or longer, while the secondary outcome was an LoS of 3 days or longer. The prediction models were developed using 6 ML algorithms, with the training and test set split in a 7:3 ratio. The performance of each model was evaluated based on the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC). Shapley Additive Explanations (SHAP) analysis measured feature importance, while calibration plots assessed the reliability of the prediction models. External validation of the developed models occurred at an independent institution, the Seoul National University Hospital. Results: The final sample included 129,938 patient entry events in the planned admissions. The Extreme Gradient Boosting (XGB) model achieved the best performance in binary classification for predicting an LoS of 7 days or longer, with an AUROC of 0.891 (95% CI 0.887-0.894) and an AUPRC of 0.819 (95% CI 0.813-0.826) on the internal test set. The Light Gradient Boosting (LGB) model performed the best in the multiclassification for predicting an LoS of 3 days or more, with an AUROC of 0.901 (95% CI 0.898-0.904) and an AUPRC of 0.770 (95% CI 0.762-0.779). The most important features contributing to the models were the operation performed, frequency of previous outpatient visits, patient admission department, age, and day of admission. The RF model showed robust performance in the external validation set, achieving an AUROC of 0.804 (95% CI 0.802-0.807). Conclusions: The use of the OMOP CDM in predicting hospital LoS for planned admissions demonstrates promising predictive capabilities for stays of varying durations. It underscores the advantage of standardized data in achieving reproducible results. This approach should serve as a model for enhancing operational efficiency and patient care coordination across health care settings.
- 22 November 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e59260
Open AccessHospital Length of Stay Prediction for Planned Admissions Using Observational Medical Outcomes Partnership Common Data Model: Retrospective Study
Background: Accurate hospital length of stay (LoS) prediction enables efficient resource management. Conventional LoS prediction models with limited covariates and nonstandardized data have limited reproducibility when applied to the general population. Objective: In this study, we developed and validated a machine learning (ML)–based LoS prediction model for planned admissions using the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM). Methods: Retrospective patient-level prediction models used electronic health record (EHR) data converted to the OMOP CDM (version 5.3) from Seoul National University Bundang Hospital (SNUBH) in South Korea. The study included 137,437 hospital admission episodes between January 2016 and December 2020. Covariates from the patient, condition occurrence, medication, observation, measurement, procedure, and visit occurrence tables were included in the analysis. To perform feature selection, we applied Lasso regularization in the logistic regression. The primary outcome was an LoS of 7 days or longer, while the secondary outcome was an LoS of 3 days or longer. The prediction models were developed using 6 ML algorithms, with the training and test set split in a 7:3 ratio. The performance of each model was evaluated based on the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC). Shapley Additive Explanations (SHAP) analysis measured feature importance, while calibration plots assessed the reliability of the prediction models. External validation of the developed models occurred at an independent institution, the Seoul National University Hospital. Results: The final sample included 129,938 patient entry events in the planned admissions. The Extreme Gradient Boosting (XGB) model achieved the best performance in binary classification for predicting an LoS of 7 days or longer, with an AUROC of 0.891 (95% CI 0.887-0.894) and an AUPRC of 0.819 (95% CI 0.813-0.826) on the internal test set. The Light Gradient Boosting (LGB) model performed the best in the multiclassification for predicting an LoS of 3 days or more, with an AUROC of 0.901 (95% CI 0.898-0.904) and an AUPRC of 0.770 (95% CI 0.762-0.779). The most important features contributing to the models were the operation performed, frequency of previous outpatient visits, patient admission department, age, and day of admission. The RF model showed robust performance in the external validation set, achieving an AUROC of 0.804 (95% CI 0.802-0.807). Conclusions: The use of the OMOP CDM in predicting hospital LoS for planned admissions demonstrates promising predictive capabilities for stays of varying durations. It underscores the advantage of standardized data in achieving reproducible results. This approach should serve as a model for enhancing operational efficiency and patient care coordination across health care settings.
- Open Access
- 7 April 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Hospital Length of Stay Prediction for Planned Admissions Using Observational Medical Outcomes Partnership Common Data Model: Retrospective Study (Preprint)
BACKGROUND Accurate hospital length of stay (LoS) prediction enables efficient resource management. Conventional LoS prediction models with limited covariates and nonstandardized data have limited reproducibility when applied to the general population. OBJECTIVE In this study, we developed and validated a machine learning (ML)–based LoS prediction model for planned admissions using the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM). METHODS Retrospective patient-level prediction models used electronic health record (EHR) data converted to the OMOP CDM (version 5.3) from Seoul National University Bundang Hospital (SNUBH) in South Korea. The study included 137,437 hospital admission episodes between January 2016 and December 2020. Covariates from the patient, condition occurrence, medication, observation, measurement, procedure, and visit occurrence tables were included in the analysis. To perform feature selection, we applied Lasso regularization in the logistic regression. The primary outcome was an LoS of 7 days or longer, while the secondary outcome was an LoS of 3 days or longer. The prediction models were developed using 6 ML algorithms, with the training and test set split in a 7:3 ratio. The performance of each model was evaluated based on the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC). Shapley Additive Explanations (SHAP) analysis measured feature importance, while calibration plots assessed the reliability of the prediction models. External validation of the developed models occurred at an independent institution, the Seoul National University Hospital. RESULTS The final sample included 129,938 patient entry events in the planned admissions. The Extreme Gradient Boosting (XGB) model achieved the best performance in binary classification for predicting an LoS of 7 days or longer, with an AUROC of 0.891 (95% CI 0.887-0.894) and an AUPRC of 0.819 (95% CI 0.813-0.826) on the internal test set. The Light Gradient Boosting (LGB) model performed the best in the multiclassification for predicting an LoS of 3 days or more, with an AUROC of 0.901 (95% CI 0.898-0.904) and an AUPRC of 0.770 (95% CI 0.762-0.779). The most important features contributing to the models were the operation performed, frequency of previous outpatient visits, patient admission department, age, and day of admission. The RF model showed robust performance in the external validation set, achieving an AUROC of 0.804 (95% CI 0.802-0.807). CONCLUSIONS The use of the OMOP CDM in predicting hospital LoS for planned admissions demonstrates promising predictive capabilities for stays of varying durations. It underscores the advantage of standardized data in achieving reproducible results. This approach should serve as a model for enhancing operational efficiency and patient care coordination across health care settings.
- 7 April 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessHospital Length of Stay Prediction for Planned Admissions Using Observational Medical Outcomes Partnership Common Data Model: Retrospective Study (Preprint)
BACKGROUND Accurate hospital length of stay (LoS) prediction enables efficient resource management. Conventional LoS prediction models with limited covariates and nonstandardized data have limited reproducibility when applied to the general population. OBJECTIVE In this study, we developed and validated a machine learning (ML)–based LoS prediction model for planned admissions using the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM). METHODS Retrospective patient-level prediction models used electronic health record (EHR) data converted to the OMOP CDM (version 5.3) from Seoul National University Bundang Hospital (SNUBH) in South Korea. The study included 137,437 hospital admission episodes between January 2016 and December 2020. Covariates from the patient, condition occurrence, medication, observation, measurement, procedure, and visit occurrence tables were included in the analysis. To perform feature selection, we applied Lasso regularization in the logistic regression. The primary outcome was an LoS of 7 days or longer, while the secondary outcome was an LoS of 3 days or longer. The prediction models were developed using 6 ML algorithms, with the training and test set split in a 7:3 ratio. The performance of each model was evaluated based on the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC). Shapley Additive Explanations (SHAP) analysis measured feature importance, while calibration plots assessed the reliability of the prediction models. External validation of the developed models occurred at an independent institution, the Seoul National University Hospital. RESULTS The final sample included 129,938 patient entry events in the planned admissions. The Extreme Gradient Boosting (XGB) model achieved the best performance in binary classification for predicting an LoS of 7 days or longer, with an AUROC of 0.891 (95% CI 0.887-0.894) and an AUPRC of 0.819 (95% CI 0.813-0.826) on the internal test set. The Light Gradient Boosting (LGB) model performed the best in the multiclassification for predicting an LoS of 3 days or more, with an AUROC of 0.901 (95% CI 0.898-0.904) and an AUPRC of 0.770 (95% CI 0.762-0.779). The most important features contributing to the models were the operation performed, frequency of previous outpatient visits, patient admission department, age, and day of admission. The RF model showed robust performance in the external validation set, achieving an AUROC of 0.804 (95% CI 0.802-0.807). CONCLUSIONS The use of the OMOP CDM in predicting hospital LoS for planned admissions demonstrates promising predictive capabilities for stays of varying durations. It underscores the advantage of standardized data in achieving reproducible results. This approach should serve as a model for enhancing operational efficiency and patient care coordination across health care settings.